A Phase I Trial of Intraperitoneal (IP) Mesothelin (Msln)-Targeted CAR T-cell Therapy in Patients with MSLN-positive Esophagogastric Cancer (EGC) with Peritoneal Carcinomatosis.
Journal of Clinical Oncology（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要